Open access
Jul 2026
Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer
C9-66 CAR-T cells with metabolic optimisation and TME reprogramming represent a tumour-specific and clinically translatable immunotherapeutic strategy for PDAC and other ofCS-expressing solid tumours.
Ke Jiang, Chu-Hu Lai, Shuang Dong et al.
· Gut · 0 citations